Targeted therapies in non-muscle-invasive bladder cancer according to the signaling pathways

Urologic Oncology: Seminars and Original Investigations

Volumn 29, Issue 1, 2011, Pages 4-11

  Wallerand, Hervé ^a   Bernhard, Jean Christophe ^a   Culine, Stéphane ^b   Ballanger, Philippe ^a   Robert, Grégoire ^a   Reiter, Robert E ^d   Ferrière, Jean Marie ^a   Ravaud, Alain ^c  

^a HÔPITAL PELLEGRIN   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c HÔPITAL SAINT ANDRÉ   (France)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bladder neoplasm; Molecular biology; Non muscle invasive bladder cancer; Targeted therapy

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER; 2 MORPHOLINO 8 PHENYLCHROMONE; 3 [4 METHYL 2 (2 OXO 3 INDOLINYLMETHYLIDENYL) 3 PYRROLYL]PROPIONIC ACID; ANTINEOPLASTIC AGENT; AZD 3409; BIM 46228; CARBOPLATIN; CETUXIMAB; DOVITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; EVEROLIMUS; FIBROBLAST GROWTH FACTOR RECEPTOR 3; GEFITINIB; GEMCITABINE; L 778123; LAPATINIB; LONAFARNIB; MATUZUMAB; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PACLITAXEL; RAF PROTEIN; RAPAMYCIN; SELUMETINIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIPIFARNIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB;

BIOLOGY; BLADDER CANCER; BLADDER TUMOR; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CANCER THERAPY; CARCINOGENESIS; CELL; CLINICAL PRACTICE; COLON CANCER; DISEASE COURSE; EPIGENETICS; FOLLOW UP; HIGH RISK PATIENT; HOMEOSTASIS; HUMAN; IMMUNOTHERAPY; LIFE; MELANOMA; METASTASIS; MORBIDITY; ONCOGENE RAS; PREDICTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; RECURRENT DISEASE; REVIEW; SIGNAL TRANSDUCTION; TRANSURETHRAL RESECTION; URINARY TRACT CANCER;

HUMANS; NEOPLASM INVASIVENESS; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS;

EID: 78650679584     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.07.025     Document Type: Review

References (71)

1. Lotan Y., Svatek R.S., Malats N. Screening for bladder cancer: A perspective. World J Urol 2008, 26:13-18.
2. Heney N.M., Ahmed S., Flanagan M.J., et al. Superficial bladder cancer: Progression and recurrence. J Urol 1983, 130:1083-1086.
3. Ro J.Y., Staerkel G.A., Ayala A.G. Cytologic and histologic features of superficial bladder cancer. Urol Clin North Am 1992, 19:435-453.
4. Knowles M.A. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?. Carcinogenesis 2006, 27:361-373.
5. Millán-Rodríguez F., Chéchile-Toniolo G., Salvador-Bayarri J., et al. Primary superficial bladder cancer risk groups according to progression, mortality, and recurrence. J Urol 2000, 164:680-684.
6. Ferlay J., Randi G., Bosetti C., et al. Declining mortality from bladder cancer in Europe. BJU Int 2008, 101:11-19.
7. Baylin S.B., Ohm J.E. Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction?. Nat Rev Cancer 2006, 6:107-116.
8. Wu X.R. Urothelial tumorigenesis: A tale of divergent pathways. Nat Rev Cancer 2005, 5:713-725.
9. Eswarakumar V.P., Lax I., Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005, 16:139-149.
10. L'Hĉte C.G., Knowles M.A. Cell responses to FGFR3 signaling: Growth, differentiation, and apoptosis. Exp Cell Res 2005, 304:417-431.
11. van Oers J.M., Adam C., Denzinger S., et al. Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder. Int J Cancer 2006, 119:1212-1215.
12. Rieger-Christ K.M., Mourtzinos A., Lee P.J., et al. Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection. Cancer 2003, 98:737-744.
13. van Rhijn B.W., van der Kwast T.H., Vis A.N., et al. FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res 2004, 64:1911-1914.
14. Bakkar A.A., Wallerand H., Radvanyi F., et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 2003, 63:8108-8112.
15. Cappellen D., De Oliveira C., Ricol D., et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999, 23:18-20.
16. Agazie Y.M., Movilla N., Ischenko I., et al. The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3. Oncogene 2003, 22:6909-6918.
17. Hart K.C., Robertson S.C., Kanemitsu M.Y., et al. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene 2000, 19:3309-3320.
18. Hernández S., López-Knowles E., Lloreta J., et al. Prospective study of FGFR3 mutations as a prognostic factor in non-muscle-invasive urothelial bladder carcinomas. J Clin Oncol 2006, 24:3664-3671.
19. Lamy A., Gobet F., Laurent M., et al. Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations. J Urol 2006, 176:2686-2689.
20. Esrig D., Elmajian D., Groshen S., et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994, 331:1259-1264.
21. Tomlinson D.C., Lamont F.R., Shnyder S.D., et al. Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer. Cancer Res 2009, 69:4613-4620.
22. Barbacid M. Ras genes. Annu Rev Biochem 1987, 56:779-827.
23. Zhang Z.T., Pak J., Huang H.Y., et al. Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene 2001, 20:1973-1980.
24. Dinney C.P., McConkey D.J., Millikan R.E., et al. Focus on bladder cancer. Cancer Cell 2006, 6:111-116.
25. Mitra A.P., Datar R.H., Cote R.J. Molecular pathways in invasive bladder cancer: New insights into mechanisms, progression, and target identification. J Clin Oncol 2006, 24:5552-5564.
26. Jebar A.H., Hurst C.D., Tomlinson D.C., et al. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 2005, 24:5218-5225.
27. Wu X., Obata T., Khan Q., et al. The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion. BJU Int 2004, 93:143-150.
28. Theodorescu D., Laderoute K.R., Gulding K.M. Epidermal growth factor receptor-regulated human bladder cancer motility is in part a phosphatidylinositol 3-kinase-mediated process. Cell Growth Differ 1998, 9:919-928.
29. Sriplakich S., Jahnson S., Karlsson M.G. Epidermal growth factor receptor expression: Predictive value for the outcome after cystectomy for bladder cancer?. BJU Int 1999, 83:498-503.
30. Kassouf W., Dinney C.P., Brown G., et al. Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of gefitinib in bladder cancer cells. Cancer Res 2005, 65:10524-10535.
31. Thatcher N., Chang A., Parikh P., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomized, placebo-controlled, multicenter study (Iressa survival evaluation in lung cancer). Lancet 2005, 366:1527-1537.
32. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672.
33. Gandour-Edwards R., Lara P.N., Folkins A.K., et al. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?. Cancer 2002, 95:1009-1015.
34. O'Brien T., Cranston D., Fuggle S., et al. Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res 1995, 55:510-513.
35. Crew J.P., O'Brien T., Bradburn M., et al. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 1997, 57:5281-5285.
36. Santos L., Costa C., Pereira S., et al. Neovascularization is a prognostic factor of early recurrence in T1/G2 urothelial bladder tumours. Ann Oncol 2003, 14:1419-1424.
37. Cochet O., Kenigsberg M., Delumeau I., et al. Intracellular expression of an antibody fragment-neutralizing p21 ras promotes tumor regression. Cancer Res 1998, 58:1170-1176.
38. Stacey D.W., DeGudicibus S.R., Smith M.R. Cellular ras activity and tumor cell proliferation. Exp Cell Res 1987, 171:232-242.
39. Eastham J.A., Ahlering T.E. Use of an anti-ras ribozyme to alter the malignant phenotype of a human bladder cancer cell line. J Urol 1996, 156:1186-1188.
40. Kita K., Saito S., Morioka C.Y., et al. Growth inhibition of human pancreatic cancer cell lines by anti-sense oligonucleotides specific to mutated K-ras genes. Int J Cancer 1999, 80:553-558.
41. Ogiso Y., Sakai N., Watari H., et al. Suppression of various human tumor cell lines by a dominant negative H-ras mutant. Gene Ther 1994, 1:403-407.
42. Sebti S.M., Adjei A.A. Farnesyltransferase inhibitors. Semin Oncol 2004, 31(Suppl 1):28-39.
43. Adjei A.A., Erlichman C., Davis J.N., et al. A Phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity. Cancer Res 2000, 60:1871-1877.
44. Cohen-Jonathan E., Evans S.M., Koch C.J., et al. The farnesyltransferase inhibitor L744832 reduces hypoxia in tumors expressing activated H-ras. Cancer Res 2001, 61:2289-2293.
45. Punt C.J., van Maanen L., Bol C.J., et al. Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors. Anticancer Drugs 2001, 12:193-197.
46. Prevost G.P., Pradines A., Brezak M.C., et al. Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of human farnesyltransferase, BIM-46228. Int J Cancer 2001, 91:718-722.
47. Zujewski J., Horak I.D., Bol C.J., et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 2000, 18:927-941.
48. End D.W., Smets G., Todd A.V., et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 2001, 61:131-137.
49. Kita K., Saito S., Morioka C.Y., et al. Growth inhibition of human pancreatic cancer cell lines by anti-sense oligonucleotides specific to mutated K-ras genes. Int J Cancer 1999, 80:553-558.
50. Crooke S.T. Potential roles of antisense technology in cancer chemotherapy. Oncogene 2000, 19:6651-6659.
51. Ogiso Y., Gutierrez L., Wrathall L.S., et al. trans-Dominant suppressor mutations of the H-ras oncogene. Cell Growth Differ 1990, 1:217-224.
52. Hwang Y.W., Zhong J.M., Poullet P., et al. Inhibition of SDC25 C-domain-induced guanine-nucleotide exchange by guanine ring binding domain mutants of v-H-ras. J Biol Chem 1993, 268:24692-24698.
53. Simon R., Richter J., Wagner U., et al. High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. Cancer Res 2001, 61:4514-4519.
54. Yeh T.C., Marsh V., Bernat B.A., et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase-kinase 1/2 inhibitor. Clin Cancer Res 2007, 13:1576-1583.
55. Cowley S., Paterson H., Kemp P., et al. Activation of MAP kinase-kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 1994, 77:841-852.
56. Eliceiri B.P., Klemke R., Strömblad S., et al. Integrin alphavbeta3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. J Cell Biol 1998, 140(5):1255-1263.
57. Gómez-Román J.J., Saenz P., Molina M., et al. Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth. Clin Cancer Res 2005, 11:459-465.
58. Zhu L., Somlo G., Zhou B., et al. Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma. Mol Cancer Ther 2005, 4:787-798.
59. Bernard-Pierrot I., Brams A., Dunois-Lardé C., et al. Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis 2006, 27:740-747.
60. Qing J., Du X., Chen Y., et al. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest 2009, 119:1216-1229.
61. Christensen J.G., Schreck R.E., Chan E., et al. High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo. Clin Cancer Res 2001, 7:4230-4238.
62. Ng S.S., Tsao M.S., Nicklee T., et al. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol Cancer Ther 2002, 1:777-783.
63. Frederick B.A., Helfrich B.A., Coldren C.D., et al. Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol Cancer Ther 2007, 6:1683-1691.
64. Kwak E.L., Sordella R., Bell D.W., et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 2005, 102:7665-7670.
65. Nelson M.H., Dolder C.R. Lapatinib: A novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann Pharmacother 2006, 40:261-269.
66. Gomez H.L., Doval D.C., Chavez M.A., et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 2008, 26:2999-3005.
67. Colomer R., Montero S., Lluch A., et al. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 2000, 6:2356-2362.
68. Tuma R.S. Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials. J Natl Cancer Inst 2007, 99:348-349.
69. Motzer R.J., Rini B.I., Bukowski R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006, 295:2516-2524.
70. Flaig T.W., Su L.J., McCoach C., et al. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner. BJU Int 2009, 130:1729-1737.
71. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64:7099-7109.